These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27007871)

  • 1. Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout.
    Tatani K; Hiratochi M; Kikuchi N; Kuramochi Y; Watanabe S; Yamauchi Y; Itoh F; Isaji M; Shuto S
    J Med Chem; 2016 Apr; 59(8):3719-31. PubMed ID: 27007871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.
    Tatani K; Hiratochi M; Nonaka Y; Isaji M; Shuto S
    ACS Med Chem Lett; 2015 Mar; 6(3):244-8. PubMed ID: 25815140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypouricemic effects of novel concentrative nucleoside transporter 2 inhibitors through suppressing intestinal absorption of purine nucleosides.
    Hiratochi M; Tatani K; Shimizu K; Kuramochi Y; Kikuchi N; Kamada N; Itoh F; Isaji M
    Eur J Pharmacol; 2012 Sep; 690(1-3):183-91. PubMed ID: 22709993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum.
    Shin HC; Landowski CP; Sun D; Vig BS; Kim I; Mittal S; Lane M; Rosania G; Drach JC; Amidon GL
    Biochem Biophys Res Commun; 2003 Aug; 307(3):696-703. PubMed ID: 12893280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1.
    Chang C; Swaan PW; Ngo LY; Lum PY; Patil SD; Unadkat JD
    Mol Pharmacol; 2004 Mar; 65(3):558-70. PubMed ID: 14978234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
    Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
    Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2.
    Owen RP; Badagnani I; Giacomini KM
    J Biol Chem; 2006 Sep; 281(36):26675-82. PubMed ID: 16840788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cation coupling properties of human concentrative nucleoside transporters hCNT1, hCNT2 and hCNT3.
    Smith KM; Slugoski MD; Cass CE; Baldwin SA; Karpinski E; Young JD
    Mol Membr Biol; 2007; 24(1):53-64. PubMed ID: 17453413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity.
    Wang C; Pimple S; Buolamwini JK
    Biochem Pharmacol; 2010 Feb; 79(3):307-20. PubMed ID: 19735647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole.
    Shin HC; Kim JS; Vig BS; Song X; Drach JC; Amidon GL
    Biol Pharm Bull; 2006 Feb; 29(2):247-52. PubMed ID: 16462026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic organization and functional characterization of the human concentrative nucleoside transporter-3 isoform (hCNT3) expressed in mammalian cells.
    Toan SV; To KK; Leung GP; de Souza MO; Ward JL; Tse CM
    Pflugers Arch; 2003 Nov; 447(2):195-204. PubMed ID: 14504928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribavirin uptake into human hepatocyte HHL5 cells is enhanced by interferon-α via up-regulation of the human concentrative nucleoside transporter (hCNT2).
    Pinilla-Macua I; Fernández-Calotti P; Pérez-Del-Pulgar S; Pastor-Anglada M
    Mol Pharm; 2014 Sep; 11(9):3223-30. PubMed ID: 24957263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.
    Damaraju VL; Visser F; Zhang J; Mowles D; Ng AM; Young JD; Jayaram HN; Cass CE
    Mol Pharmacol; 2005 Jan; 67(1):273-9. PubMed ID: 15486050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactiplantibacillus plantarum enables blood urate control in mice through degradation of nucleosides in gastrointestinal tract.
    Li M; Wu X; Guo Z; Gao R; Ni Z; Cui H; Zong M; Van Bockstaele F; Lou W
    Microbiome; 2023 Jul; 11(1):153. PubMed ID: 37468996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New medications in development for the treatment of hyperuricemia of gout.
    Diaz-Torné C; Perez-Herrero N; Perez-Ruiz F
    Curr Opin Rheumatol; 2015 Mar; 27(2):164-9. PubMed ID: 25603039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
    Perez-Ruiz F; Herrero-Beites AM; Carmona L
    Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity.
    Hou CW; Lee YC; Hung HF; Fu HW; Jeng KC
    Am J Chin Med; 2012; 40(5):979-91. PubMed ID: 22928829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.